Women's Rights Group Calls for Universal Access to Female Condoms CHICAGO, Feb. 15 /PRNewswire-FirstCall/ -- The Female Health Company (OTC:FHCO) (BULLETIN BOARD: FHCO) today announced that its partner in India, Hindustan Latex Limited (HLL) has expanded its promotion of the Female Condom to consumers in three additional cities under the brand name Confidom. Earlier HLL had launched the Female Condom to consumers in the three cities of Bangalore, Chennai and Kolkata. It has now been launched in New Delhi, Mumbai and Hyderabad, for a total of six cities that have an aggregate population of approximately 67 million people. HLL plans to launch in a total of thirty four (34) cities over time. As previously announced, the Company expects a third FC2 production line, developed with HLL at Kochi in India, to be operational by the end of the second quarter. FC2 is the Company's second-generation Female Condom product, which is currently being manufactured on two production lines in Malaysia. In addition, the Company noted that the Center for Health and Gender Equity (CHANGE) issued a press release on February 08, 2007, calling for immediate investment to provide universal access to female condoms. CHANGE noted disappointment in the recent discontinuation of certain microbicide clinical trials and the importance of continuing research to successfully develop such products. However, it noted that the recent results underscore the fact that women cannot wait for new HIV prevention products, and that currently available products should be made universally available. The release can be accessed at CHANGE's website; http://www.genderhealth.org/ . About The Female Health Company, Inc. The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC Female Condom(R), which is primarily distributed by public health organizations and donor groups in over 90 developing countries around the world. Worldwide, the Female Condom is available in various programs in 108 countries. The Company owns certain worldwide rights to the FC Female Condom(R), including patents that have been issued in the United States, United Kingdom, Japan, France, Italy, Germany, Spain, the European Patent Convention, the People's Republic of China, Canada, South Korea and Australia. FC Female Condom(R) is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. "Safe Harbor" statement under the Private Securities Litigation Reform Action of 1995: The statements in this release which are not historical fact are forward-looking statements based upon the Company's current plans and strategies, and reflect the Company's current assessment of the risks and uncertainties related to its business, including such things as product demand and market acceptance; the economic and business environment and the impact of government pressures; currency risks; capacity; efficiency and supply constraints; and other risks detailed in the Company's press releases, shareholder communications and Securities and Exchange Commission filings. Actual events affecting the Company and the impact of such events on the Company's operations may vary from those currently anticipated. For more information about the Female Health Company visit the Company's web site at http://www.femalehealth.com/ and http://www.femalecondom.org/ . If you would like to be added to an e-mail alert list, please send an e- mail to . DATASOURCE: The Female Health Company CONTACT: William R. Gargiulo, Jr., +1-231-526-1244, or Donna Felch, +1-312-595-9123, both of The Female Health Company Web site: http://www.femalehealth.com/ http://www.femalecondom.org/ http://www.genderhealth.org/

Copyright